CATEGORY AND TAGS
Tesamorelin Peptide raw powder, raw Tesamorelin peptide, Tesamorelin Dosage Dose, buy Tesamorelin 2mg, Tesamorelin 5mg blue top, Tesamorelin 10mg red top, Tesamorelin cycle, Tesamorelin factory price, research chemical Tesamorelin peptide, Tesamorelin 10vials, where to buy Tesamorelin, Tesamorelin peptide supplier, Tesamorelin online store, buy Tesamorelin Canada, Tesamorelin Poland, Tesamorelin USA, human growth peptide Tesamorelin, Tesamorelin manufacturer, Tesamorelin raw powder for sale, Tesamorelin effects, Tesamorelin fat loss, Tesamorelin 10kits price
Tesamorelin Specifications
CAS: 218949-48-5
MF: C211H366N72O67S1
MW: 5135.89
Purity: 99%
Tesamorelin Description
Tesamorelin (INN) (trade name Egrifta) is a synthetic form of growth-hormone-releasing hormone (GHRH) which is used in the treatment of HIV-associated lipodystrophy. It is produced and developed by Theratechnologies, Inc. of Canada. The drug is a synthetic peptide consisting of all 44 amino acids of human GHRH with the addition of a trans-3-hexenoic acid group.
Tesamorelin has been shown to reduce lipodystrophy in HIV-infected individuals. Lipodystrophy is a condition that causes changes in placement of body fat, including wasting and fat accumulation, and changes in metabolism.
Similar to Tesamorelin is Sermorelin, which may be taken with GHRP-6 is clinical trials, that also promotes production and possible fat loss. Individuals with lipodystrophy may develop excess fat most notably around the liver, stomach, and other abdominal organs (visceral body fat).
Tesamorelin Application
Tesamorelin, (formerly known as TH9507), is a type of peptide called a growth hormone-releasing factor (GHRF). GHRF causes growth hormone to be created and spread in the body, which helps increase metabolism, reduce belly fat, improve body shape, and use of energy. Tesamorelin (formerly known as TH9507) is a synthetic growth hormone-releasing factor that stimulates the pituitary gland in the brain to secrete growth hormone; this indirect approach appears to maintain more stable, natural levels, like CJC-1295 DAC,. Clinical trials have shown that tesamorelin significantly reduces abdominal fat with fewer side effects than human growth hormone itself, although abdominal fat may return after the Tesamorlein is discontinued (depending upon the individual). Tesamorelin has been shown to reduce lipodystrophy in HIV-infected individuals as well as similarly reducing abdominal fat in NON-HIV-Infected individuals.
Studied as a way to reduce excess deep belly fat, the synthetic human growth hormone releasing factor called tesamorelin (Egrifta) was approved by the FDA in November 2010 and has been available since January 2011. Results from a 52-week study of 816 people showed 18% less deep belly fat in those on tesamorelin than those taking placebo.
